[
  {
    "ts": null,
    "headline": "Why Novo Nordisk Is A Strong Buy Despite Market Concerns",
    "summary": "Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO stock a buy.",
    "url": "https://finnhub.io/api/news?id=3122007dae2978956606ea7a5228db0ac0ef5a4180bc8ae0df8c2091a0d4e554",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740009540,
      "headline": "Why Novo Nordisk Is A Strong Buy Despite Market Concerns",
      "id": 132792928,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1156718067/image_1156718067.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO stock a buy.",
      "url": "https://finnhub.io/api/news?id=3122007dae2978956606ea7a5228db0ac0ef5a4180bc8ae0df8c2091a0d4e554"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors despite daily gains",
    "summary": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=b44096833d43c1a1d371db7c4dac5324869f1d4bea252902e612166b3c35fa17",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739983140,
      "headline": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors despite daily gains",
      "id": 132799353,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=b44096833d43c1a1d371db7c4dac5324869f1d4bea252902e612166b3c35fa17"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces Opdivo速 Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer",
    "summary": "Bristol Myers Squibb today announced the final analysis of overall survival from the Phase 3 CheckMate -816 study, which evaluated Opdivo速 in combination with platinum-doublet chemotherapy as a...",
    "url": "https://finnhub.io/api/news?id=54f513b7ca11129628f9b3914daa700006b00c82707ea4036be06467fcff07a6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739948403,
      "headline": "Bristol Myers Squibb Announces Opdivo速 Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer",
      "id": 132783453,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb today announced the final analysis of overall survival from the Phase 3 CheckMate -816 study, which evaluated Opdivo速 in combination with platinum-doublet chemotherapy as a...",
      "url": "https://finnhub.io/api/news?id=54f513b7ca11129628f9b3914daa700006b00c82707ea4036be06467fcff07a6"
    }
  }
]